BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $13.00 by Analysts at Royal Bank Of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective cut by Royal Bank Of Canada from $14.00 to $13.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

BCRX has been the topic of a number of other reports. TD Cowen assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price objective on the stock. Barclays dropped their price target on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 4th. Citizens Jmp decreased their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. JMP Securities increased their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 15th. Finally, Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $19.50.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $6.58 on Friday. The stock has a market capitalization of $1.39 billion, a PE ratio of -131.60, a price-to-earnings-growth ratio of 0.36 and a beta of 0.80. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.31. The stock has a 50 day moving average price of $7.28 and a two-hundred day moving average price of $7.59.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The firm had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. During the same period in the previous year, the company earned ($0.07) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 36.1% compared to the same quarter last year. Research analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 91,004 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $7.10, for a total value of $646,128.40. Following the completion of the transaction, the insider directly owned 416,152 shares of the company’s stock, valued at $2,954,679.20. This represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 183,453 shares of company stock valued at $1,330,965. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BCRX. Jump Financial LLC increased its stake in shares of BioCryst Pharmaceuticals by 805.0% in the second quarter. Jump Financial LLC now owns 1,347,112 shares of the biotechnology company’s stock worth $12,070,000 after purchasing an additional 1,198,263 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in BioCryst Pharmaceuticals by 48.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,584,206 shares of the biotechnology company’s stock worth $14,194,000 after buying an additional 518,623 shares during the period. Russell Investments Group Ltd. boosted its holdings in BioCryst Pharmaceuticals by 326.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 440,249 shares of the biotechnology company’s stock worth $3,945,000 after buying an additional 336,920 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in BioCryst Pharmaceuticals by 2,103.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after buying an additional 4,084,403 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at $1,493,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.